Search

Displaying results 2931 - 2940 of 3917 in total
  1. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    Chronic venous insufficiency is a common condition the western population. Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease. Diosmin is a bio...

    Products: FLEBODIA® COMPRIMIDOS RECUBIERTOS CON PELÍCULA
  2. Drug

    Lormetazepam

    go.drugbank.com/drugs/DB13872
    Approved

    Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia . It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.

  3. Drug

    Acetohexamide

    go.drugbank.com/drugs/DB00414
    ApprovedWithdrawn

    A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.

  4. Drug

    Polydextrose

    go.drugbank.com/drugs/DB14836
    Experimental

    Polydextrose is under investigation in clinical trial NCT02258750 (Assessing a Polydextrose Containing Soup on Food Intake, Appetite and Biomarkers of Satiation and Satiety).

  5. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

  6. Drug

    Hexocyclium

    go.drugbank.com/drugs/DB06787
    Approved

    Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Prot...

  7. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    However the major component is considered to be squalene, which may range up to 90% of the shark oil, depending on the species.

  8. Drug

    Abatacept

    go.drugbank.com/drugs/DB01281
    ApprovedInvestigational

    The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.

  9. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition

  10. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349]